GPRC5D and FCRH5 Targeted Therapies in Myeloma
BCMA is a common target in new immunotherapies like CAR-T and certain bispecific antibodies. However, BCMA is not the only target of the myeloma cell that scientists can use to target the myeloma. Learn more about targets GPRC5D and FCRH5 in mutliple myeloma treatments.
Audrey introduces the agenda of the event and featured speaker Dr. Benjamin Diamond.
Dr. Diamond talks about targets GPRC5D and FCRH5 in mutliple myeloma treatments.
Type your questions in the chat and we will answer them!
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Benjamin Diamond, MD
Dr. Diamond is a hematologist/oncologist who specializes in the treatment of plasma cell disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. His research interests include utilization of minimal residual disease (MRD)-guided approaches to clinical decision-making, maintenance therapy, and the genomics of multiple myeloma and secondary malignancies that occur in patients treated for multiple myeloma. He completed fellowship at Memorial Sloan Kettering Cancer Center, spending a year as chief fellow, and is a member of the Myeloma Genomics Laboratory at Sylvester Comprehensive Cancer Center.